DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
View original source (GlobeNewswire)Company analysis
Earlier from Dbv Technologies Sa
- DBV Technologies to Participate in Upcoming September Investor Conferences
- DBV Technologies annonce sa participation à plusieurs conférences investisseurs en septembre
- Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026
- DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq